Project Grant R21CA292282
Award Date
3/12/25
Completion Date
2/28/27
Dollars Obligated
$238K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $702,748 to Weill Medical College of Cornell University to conduct research aimed at determining the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer immunotherapies. The project has three key objectives: 1) Characterize gene pathways and tumor-derived factors defining functional subsets of anti-tumorigenic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $590,625 to the University of California, Davis to support a research project titled "A Novel Therapeutic Strategy to Target Mutant p53". The project aims to investigate how the CDK4/6-RBM38-eIF4G axis regulates mutant p53 expression, determine if disrupting the RBM38-eIF4G interaction can suppress mutant p53 and related tumors, and evaluate whether a small molecule...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $645,949 to Emory University to conduct research that aims to understand how the protein SAMHD1 governs radiation and immunological dynamics in breast cancer, particularly triple-negative breast cancer (TNBC). The goal is to determine the molecular mechanisms by which SAMHD1 suppresses the immune response and reduces the efficacy of immune checkpoint inhibitors (ICI) and ionizing...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) aims to develop an engineered bacterial reporter gene fusion for radiotheranostics to improve cancer treatment. The $434,903 award to Weill Medical College of Cornell University, spanning June 2024 to May 2026, focuses on genetically engineering Salmonella bacteria to serve as an in vivo artificial receptor for a small radionuclide carrier. This novel approach seeks to concentrate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $569,441 to the University of Wisconsin-Madison for a 5-year research project (8/1/2024 - 7/31/2029) focused on investigating the mechanisms by which the p53-phosphoinositide (PIP) signaling complex regulates nuclear AKT activation and tumor progression. The key research objectives include: Determining how the p53-PIP signaling complex activates nuclear AKT through the regulatory...
This federal Project Grant award for $176,712.00, awarded on March 18, 2025 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to investigate mechanisms by which tumor-derived heat shock proteins (HSPs) prime T cell-mediated cancer immunosurveillance. The research focuses on developing a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived HSPs for providing co-stimulation and cytokines required to prime...
This federal Project Grant award, with ID F30CA298572, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $101,856 award supports research by The Trustees of Columbia University in New York to dissect the impact of genomic variants on the anti-tumor activity of T cells. The research aims to define the mechanisms by which specific single-nucleotide variants in the PIK3CD gene modulate T cell function, and evaluate their in vivo...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to identify novel compounds that can selectively induce cell death in cancer cells deficient in the p53 tumor suppressor gene, known as "p53 synthetic lethality." The $560,458 award to Children's Mercy Hospital aims to determine the requirement of reactive oxygen species (ROS)-mediated DNA double-strand breaks and inhibition of the DNA damage response...
This federal Project Grant award of $544,658, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research at New York University School of Medicine to understand how perturbations to pyrimidine sensing and response mechanisms impact cancer metabolism, anti-tumor immune cell function, and response to therapy. The research aims to: 1) determine how pyrimidine overflow and cell cycle checkpoint modulation differentially affect cancer and immune cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $585,976 to Providence Health & Services - Oregon to conduct research aimed at enhancing the efficacy of radiation therapy through the spatial restriction of anti-TGF-beta treatment to the tumor microenvironment. The key objectives are to determine whether tumor-draining lymph node-resident stem-like CD8+ T cells are required for radiation response, and to test radiation in...